Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
Adicet Bio (Nasdaq: ACET), a biotechnology company focused on developing allogeneic gamma delta T cell therapies, has announced its participation in the upcoming 2025 Canaccord Genuity Horizons in Oncology Virtual Conference.
The company's President and CEO, Chen Schor, will be featured in a panel discussion titled 'CAR T Approaches in the Autoimmune Space' scheduled for Monday, April 7, 2025, at 3:00 p.m. ET. This virtual conference appearance highlights Adicet's ongoing work in both autoimmune diseases and cancer treatments.
Adicet Bio (Nasdaq: ACET), un'azienda biotecnologica focalizzata nello sviluppo di terapie con cellule T gamma delta allogeniche, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale Horizons in Oncology di Canaccord Genuity 2025.
Il Presidente e CEO dell'azienda, Chen Schor, parteciperà a una discussione di panel intitolata 'Approcci CAR T nello Spazio Autoimmune', programmata per lunedì 7 aprile 2025, alle 15:00 ET. Questa partecipazione alla conferenza virtuale mette in evidenza il lavoro continuo di Adicet sia nelle malattie autoimmuni che nei trattamenti contro il cancro.
Adicet Bio (Nasdaq: ACET), una empresa biotecnológica centrada en el desarrollo de terapias con células T gamma delta alogénicas, ha anunciado su participación en la próxima Conferencia Virtual Horizons in Oncology de Canaccord Genuity 2025.
El Presidente y CEO de la empresa, Chen Schor, será parte de una mesa redonda titulada 'Enfoques CAR T en el Espacio Autoinmune' programada para el lunes 7 de abril de 2025, a las 3:00 p.m. ET. Esta aparición en la conferencia virtual destaca el trabajo continuo de Adicet en enfermedades autoinmunes y tratamientos contra el cáncer.
Adicet Bio (Nasdaq: ACET), 동종 감마 델타 T 세포 치료제를 개발하는 생명공학 회사가 다가오는 2025년 Canaccord Genuity 암학회 가상 컨퍼런스에 참여한다고 발표했습니다.
회사의 회장 겸 CEO인 Chen Schor는 '자가면역 영역에서의 CAR T 접근법'이라는 제목의 패널 토론에 참여할 예정이며, 이는 2025년 4월 7일 월요일 오후 3시 ET에 예정되어 있습니다. 이번 가상 컨퍼런스 참여는 Adicet의 자가면역 질환 및 암 치료에 대한 지속적인 노력을 강조합니다.
Adicet Bio (Nasdaq: ACET), une entreprise de biotechnologie axée sur le développement de thérapies par cellules T gamma delta allogéniques, a annoncé sa participation à la prochaine Conférence Virtuelle Horizons in Oncology de Canaccord Genuity 2025.
Le Président et CEO de l'entreprise, Chen Schor, sera présent lors d'une discussion en panel intitulée 'Approches CAR T dans le domaine auto-immun', prévue pour le lundi 7 avril 2025, à 15h00 ET. Cette participation à la conférence virtuelle met en lumière le travail continu d'Adicet dans les maladies auto-immunes ainsi que dans les traitements contre le cancer.
Adicet Bio (Nasdaq: ACET), ein Biotechnologieunternehmen, das sich auf die Entwicklung von allogenen Gamma-Delta-T-Zelltherapien konzentriert, hat seine Teilnahme an der bevorstehenden 2025 Canaccord Genuity Horizons in Oncology Virtuellen Konferenz bekannt gegeben.
Der Präsident und CEO des Unternehmens, Chen Schor, wird an einer Podiumsdiskussion mit dem Titel 'CAR T-Ansätze im Autoimmunbereich' teilnehmen, die für Montag, den 7. April 2025, um 15:00 Uhr ET angesetzt ist. Diese virtuelle Konferenzteilnahme hebt die laufenden Arbeiten von Adicet sowohl im Bereich der Autoimmunerkrankungen als auch in der Krebsbehandlung hervor.
- None.
- None.
Details of the event are as follows:
Panel: “CAR T Approaches in the Autoimmune Space”
Date: Monday, April 7, 2025
Time: 3:00 p.m. ET
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331839401/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
When is Adicet Bio (ACET) presenting at the Canaccord Genuity Oncology Conference 2025?
What panel will Adicet Bio (ACET) participate in at the Canaccord Conference 2025?
Who will represent Adicet Bio (ACET) at the 2025 Canaccord Genuity Conference?
What therapeutic areas does Adicet Bio (ACET) focus on?
